General Description
Indecainide hydrochloride is a class Ic antiarrhythmic agent that was developed for the suppression of ventricular arrhythmias. It is a congener of flecainide, with similar sodium channel blocking properties. The drug was never widely marketed and is now of primarily historical interest due to the emergence of safer agents.
Mechanism of Action
Indecainide potently blocks the fast inward sodium channel in cardiac Purkinje fibers and ventricular muscle, significantly slowing phase 0 depolarization. This results in slowed conduction velocity throughout the His‑Purkinje system and ventricles, prolonging QRS duration. The drug has minimal effect on repolarization (QT interval). It also exhibits some local anesthetic and membrane‑stabilizing properties.
Application
Indecainide was investigated for the treatment of life‑threatening ventricular arrhythmias, including sustained ventricular tachycardia, in patients who did not respond to class I agents. No current clinical use exists, and the drug serves only as a research tool for understanding sodium channel pharmacology.